Blockchain

Aleph Zero Joins CAMARA as the First Blockchain Organization

on

    More in Blockchain:

    Brussels, Belgium, September 6th, 2024, Chainwire

     

    Aleph Zero will work alongside the world’s largest telecommunications organizations to help to develop standardized blockchain APIs for the industry

    Aleph Zero, a blockchain ecosystem engineered for speed, data confidentiality, and ease of development, has officially joined the CAMARA Foundation as a General Member. This strategic move marks a significant step towards integrating advanced blockchain technology with global telecommunications standards, particularly in the realm of Decentralized Identifiers (DIDs).

    As a General Member, Aleph Zero will work closely with global telecom and tech leaders within CAMARA to develop and contribute to blockchain-specific initiatives. A key focus of this collaboration will be the Blockchain Public Address API, which has the potential to revolutionize how users interact with blockchain technologies through their mobile devices.

    The CAMARA Project, launched in 2021 under the Linux Foundation and GSMA, aims to create standardized APIs for telecommunications networks. This initiative is designed to simplify network complexities and provide seamless access to network capabilities across different operators and countries. A cornerstone of this effort is the Blockchain Public Address API, which was initiated in June 2023 and is currently in version 0.1.0. The CAMARA Project now includes over 230 companies – including Deutsche Telekom, stc, Vodafone and Telefónica – and 650 individual participants.

    This API allows for the management of blockchain addresses associated with phone numbers, offering features such as retrieval of blockchain public addresses linked to phone numbers, and the binding and unbinding of these addresses. By utilizing blockchain public addresses as Decentralized Identifiers (DIDs), the API enables telecom service providers to offer third parties the capability to pair phone numbers with blockchain addresses, thereby simplifying transactions for end-users.

    Aleph Zero’s expertise in zero-knowledge proofs and privacy-preserving technologies will contribute significantly to the further development and refinement of the group’s blockchain-related solutions.

    Antoni Zolciak, co-founder at Aleph Zero, said: “The integration of blockchain technology into mainstream infrastructure is accelerating at an unprecedented rate. Forward-thinking organizations across various sectors are recognizing the transformative potential of distributed ledger technologies. We’re looking forward to collaborating with various members of the Foundation and contributing to the telecommunications APIs from a blockchain standpoint.”

    Aleph Zero, known for its cutting-edge blockchain ecosystem, offers secure, scalable, and privacy-focused solutions for Web3 applications. With its zkOS and EVM Layer 2 network, Aleph Zero continues to push the boundaries of blockchain technology, focusing on privacy, scalability, and interoperability. Aleph Zero recently launched its EVM-layer, an exceptionally fast and efficient blockchain, boasting a block time of up to 250 milliseconds with near-instant transaction finality.

    For more information about the CAMARA Project, visit https://camaraproject.org/

    About Aleph Zero

    Aleph Zero is an ecosystem of blockchain solutions that are engineered for speed, data confidentiality, and ease of development. It achieves efficiencies akin to conventional web2 systems, upholds rigorous standards for data protection via highly optimized Zero Knowledge Proofs, and offers a comprehensive toolset for development across web3 that range from WASM to EVM environments. Aleph Zero’s versatility is highlighted by over 40 use cases being actively developed, showcasing its adaptability across various sectors and applications. These use cases are part of an engaged community and growing ecosystem of web3 applications that are supported by Aleph Zero programs.

    For all media inquiries, users can contact josh@serotonin.co

     

    Contact

    PR Manager
    Josh Adams
    Aleph Zero
    josh@serotonin.co

    PostAd_coinrule_banner728x90

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    *

    Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

    2024-09-17T13:00:00Z

    Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform

    AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.

    Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”

    Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”

    RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.

    The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.

    In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.

    Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.

    PersonalAIze aims to contribute in several key areas:

    • Advancing AI models by leveraging the latest state-of-the-art techniques.
    • Supporting the professional growth of the software team.
    • Enhancing the explainability of AI models, engaging clinicians in model development.
    • Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.

    This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.

    About Renovaro
    Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

    RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

    About PersonalAIze
    PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.

    Forward-Looking Statements

    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    For media inquiries, please contact: karen@renovarocube.com

    Source: Renovaro Inc.


    GlobeNewsWire News

    Recent Comments